Implantable devices that measure the cumulative release of biomarkers promise new diagnostic options.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ling, Y. et al. Nat. Biotechnol. 29, 273–277 (2011).
Daniel, K.D. et al. Biosens. Bioelectron. 24, 3252–3257 (2009).
Thygesen, K. et al. Eur. Heart J. 31, 2197–2204 (2010).
Apple, F.S. Clin. Chem. 55, 1303–1306 (2009).
Morrow, D.A. & Antman, E.M. Clin. Chem. 55, 5–8 (2009).
Wilson, S.R. et al. Am. Heart J. 158, 386–391 (2009).
Reichlin, T. et al. N. Engl. J. Med. 361, 858–867 (2009).
de Lemos, J.A. et al. J. Am. Med. Assoc. 304, 2503–2512 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.S.A. has consulted for and received research grant funding for several biomarker companies that market the biomarkers discussed in the paper reviewed. These include Abbott Diagnostics, Beckman Coulter, Siemens, Ortho-Clinical Diagnostics, Radiometer, Roche, BRAHMS, Alere/Biosite and Response Biomedical.
Rights and permissions
About this article
Cite this article
Apple, F. Biomarkers in aggregate. Nat Biotechnol 29, 236–237 (2011). https://doi.org/10.1038/nbt.1803
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1803
This article is cited by
-
Magnetic nanoparticles for multi-imaging and drug delivery
Molecules and Cells (2013)